Archives: Search / 2023 / 2022 / 2021 / 2020 / 2019 / 2018 / 2017 / 2016 / 2015
2019 Archives
Dec 23, 2019 Lannett Company, Inc. (NYSE: LCI) today announced that it has received approvals from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Applications (ANDAs) for Butalbital,... More |
Dec 12, 2019 Lannett Company, Inc. (NYSE: LCI) today announced that it expects to commence marketing in the coming months a generic version of Adderall XR®, an extended-release mixed salt of a single entity... More |
Dec 4, 2019 --Study Achieves All Primary Endpoints; Company to Set Meeting with FDA Regarding Pivotal Trial Design-- Lannett Company, Inc. (NYSE: LCI) today announced positive results from the first human study evaluating insulin glargine that Lannett is developing with its strategic alliance partners within the... More |
Financial and Business Highlights: Net Sales, Profitability Exceeded Expectations Launched First-to-Market Posaconazole Expanded Pipeline with Significant Future Opportunities: • Levothyroxine... More |
Oct 30, 2019 Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2020 first quarter on Wednesday, November 6, 2019, after the market closes. Lannett... More |
Oct 1, 2019 Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an exclusive U.S. distribution agreement for the therapeutically equivalent generic of ADVAIR DISKUS® (Fluticasone... More |
Sep 27, 2019 Lannett Company, Inc. (NYSE: LCI) ("Lannett" or the "Company") today announced the closing of $86.25 million aggregate principal amount of 4.50% convertible senior notes due 2026 (the "Notes") in... More |
Sep 25, 2019 Lannett Company, Inc. (NYSE: LCI) ("Lannett" or the "Company") today announced the pricing of $75 million aggregate principal amount of 4.50% convertible senior notes due 2026 (the "Notes") in a... More |
Sep 24, 2019 Lannett Company, Inc. (NYSE: LCI) today announced that it intends to offer, subject to market conditions and other factors, $75 million aggregate principal amount of convertible senior notes due... More |
Aug 28, 2019 Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an agreement with Sinotherapeutics Inc., a China-based specialty pharmaceutical company, to be the exclusive U.S.... More |
Fiscal 2019 Fourth Quarter Highlights: Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2019 fourth quarter and full year ended June 30, 2019. "In fiscal 2019, we made excellent progress rebuilding our... More |
Aug 27, 2019 Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into a three-year advisory services agreement with its strategic alliance partner, Cediprof, Inc., a wholly owned subsidiary... More |
Aug 20, 2019 Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2019 fourth quarter and full year on Tuesday, August 27, 2019, after the market closes.... More |
Aug 1, 2019 Lannett Company, Inc. (NYSE: LCI) today announced the appointment of John Kozlowski as chief financial officer (CFO), effective August 31, 2019. He succeeds Martin Galvan, who, as previously... More |
Jul 8, 2019 Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into a future exclusive supply and distribution agreement for the approved Levothyroxine Sodium Tablets USP of Cediprof, Inc.,... More |
Jul 3, 2019 Lannett Company, Inc. (NYSE: LCI) today commented on the U.S. Food and Drug Administration's (FDA) denial of a Citizen Petition submitted by Genus Lifesciences requesting that the FDA refuse to... More |
Jun 28, 2019 Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into a three-year agreement with Elite Pharmaceuticals to be the exclusive U.S. distributor of a Dantrolene Capsules 25 mg, 50... More |
Jun 18, 2019 Lannett Company, Inc. (NYSE: LCI) today announced that it has commenced marketing Aspirin and Extended-Release Dipyridamole Capsules, 25 mg/200 mg, the therapeutic equivalent to the reference... More |
Jun 12, 2019 Lannett Company, Inc. (NYSE: LCI) today announced its participation at two upcoming investor conferences. Schedule below: Raymond James 2019 Life Sciences and MedTech Conference, at 11:30 a.m. ET,... More |
Jun 5, 2019 Lannett Company, Inc. (NYSE: LCI) today announced the commencement of a human clinical trial of biosimilar insulin glargine, a product the company is co-developing with its strategic alliance... More |
May 29, 2019 Lannett Company, Inc. (NYSE: LCI) today announced that it has commenced marketing Methylphenidate Hydrochloride Extended Release (ER) tablets USP (CII) in 18 mg, 27 mg, 36 mg and 54 mg strengths,... More |
May 24, 2019 Lannett Company, Inc. (NYSE: LCI) today announced that the company's chief financial officer (CFO), Martin Galvan, 67, will retire on August 30, 2019, following the planned submission of the... More |
May 23, 2019 Lannett Company, Inc. (NYSE: LCI) today announced the appointment of Melissa V. Rewolinski, PhD, to its board of directors, effective July 1, 2019. Following the appointment of Dr. Rewolinski, the... More |
May 21, 2019 Lannett Company, Inc. (NYSE: LCI) today announced that it completed the purchase of approximately $30.5 million, face value, of its Term A Loans in a private transaction. "We are particularly... More |
May 16, 2019 Lannett Company, Inc. (NYSE: LCI) today announced that it has begun marketing a generic version of Adderall®, an immediate-release (IR) mixed salt of a single entity Amphetamine tablet product... More |
| 1-25 26-36 |